Compare IQIYI Inc - ADR (IQ) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQIYI Inc - ADR vs Sana Biotechnology Inc — how do they compare? IQIYI Inc - ADR trades at $1.34 (market cap $1.30B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: IQIYI Inc - ADR is the larger of the two by market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals.
| IQ | SANA | |
|---|---|---|
Market Cap | $1.30B | $1.13B |
Sector | Media | Health |
52-Week High | $2.79 | $5.92 |
52-Week Low | $0.96 | $2.68 |
Enterprise Value | $2.88B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IQ trades at $1.325, down 2.57% in 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $206.31 million in 2025, with revenue declining to $27.29 billion, though it beat EPS expectations in two recent quarters. Analyst sentiment is mixed with a 50% buy rating, while news highlights AI platform growth and leadership changes as potential catalysts.
The outlook hinges on IQ's AI-driven content strategy and cost management reversing profitability declines. Risks include intense competition, regulatory pressures in China, and sustained negative cash flow projections for 2026. Upside potential exists if execution improves, but high debt and margin pressures warrant caution for investors.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
